| Vol. 9.46 – 9 December, 2020 |
| |
|
|
| Investigators used single-cell datasets and identified glioma stem cells (GSC) at the apex of the differentiation hierarchy of glioblastoma (GBM). By reconstructing the GSCs’ regulatory network, they identified the YAP/TAZ coactivators as master regulators of this cell state, irrespectively of GBM subtypes. [Nature Cancer] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that Dynole 34-2, a potent inhibitor of Dynamin GTPase activity, could block transduction of key signaling pathways and overcome chemoresistance of leukemia stem cells. [Nature Communications] |
|
|
|
| The authors demonstrated that tumor-derived UBR5, an E3 ligase overexpressed in human ovarian cancer (OC) associated with poor prognosis, was essential for OC progression principally by promoting tumor-associated macrophage recruitment and activation via key chemokines and cytokines. [Nature Communications] |
|
|
|
| Researchers showed that microfluidic devices could be used to sort marker‐based heterogeneous CSC into mechanically stiff and soft subpopulations. The isolated soft tumor cells but not the stiff ones could form a tumor in immunocompetent mice with 100 cells per inoculation. [EMBO Journal] |
|
|
|
| Using models of triple-negative breast cancer with different intratumoral immune contexture, the authors demonstrates that a combinatorial therapy of intermittent cyclophosphamide, checkpoint inhibitors, and vinorelbine, activated antigen presenting cells, and abrogated local and metastatic tumour growth by a T-cell-related effect. [Cancer Research] |
|
|
|
| Afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and cancer stem cell (CSC) markers. Mechanistically, afatinib treatment decreased CSC markers by downregulating SOX9 via FOXA2. [Oncogene] |
|
|
|
| The correlation of expression of transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) and clinical features and gastric cancer patients’ outcomes was evaluated. Knockdown or exogenous expression of TBL1XR1 was combined with in vitro and in vivo assays to evaluate the function of TBL1XR1. [Oncogene] |
|
|
|
| Overexpression of stemness factors NANOG, OCT4 and SOX2 by introduction of gene constructs in Hep3B cells suppressed two miRNA expression levels. Treatment of chromeceptin, an IGF signaling pathway inhibitor, decreased numbers of tumorsphere and inhibited the AKT/mTOR pathway. [Scientific Reports] |
|
|
|
| Investigators found that BEX2 was highly expressed in CD274low cells, and that BEX2 knockdown decreased the tumorigenicity and G0 phase of cholangiocarcinoma cells. [Scientific Reports] |
|
|
|
| Both glioblastoma stem cells, grown in classical 2D culture and in 3D-tumor organoids, formed functional tunneling nanotubes which allowed mitochondria transfer. [Biochemical Journal] |
| |
|
|
|
| One major challenge is determining the cancer stem cell properties that can be exploited as therapeutic targets. Another challenge is identifying suitable breast cancer stem cells (BCSC) biomarkers to assess the efficacy of novel BCSC-targeted therapies. [Pharmacological Research] |
|
|
|
| Understanding the differences in origin, mechanism of self-renewal, and signaling pathways of CSCs and somatic stem cells will provide a better approach to target these specific populations in order to protect healthy cells and minimize side effects. [Current Stem Cell Research & Therapy] |
|
|
|
|
| Y-mAbs Therapeutics, Inc. and Takeda Israel announced that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA® for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. [Y-mAbs Therapeutics, Inc.] |
|
|
|
| Flinders University’s Dr. Cedric Bardy, Director of the Laboratory for Human Neurobiology at SAHMRI, says the need to understand how brain functions affect cancer cell development is urgent because the clinical outcomes of brain cancer remain extremely low. [Flinders University (News-Medical)] |
|
|
|
|
| January 15 – 16, 2021 Virtual |
|
|
|
|
|
| Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| Columbia University Medical Center – New York, New York, United States |
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| Queen Mary University of London – London, England, United Kingdom |
|
|
|
| Peking University Shenzhen Graduate School – Shenzhen, China |
|
|
|
|